- Idraparinux
Drugbox
IUPAC_name = Nonasodium (2"S",3"S",4"S",5"R",6"R")-6- [(2"R",3"R",4"S",5"R",6"R")-6-
[(2"R",3"S",4"S",5"R",6"R")-2-carboxylato-
4,5-dimethoxy-6- [(2"R",3"R",4"S",5"R",6"S")-6-methoxy-4,5-
disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]
oxyoxan-3-yl] oxy-4,5-disulfonatooxy-
2-(sulfonatooxymethyl)oxan-3-yl] oxy-4,5-dimethoxy-
3- [(2"R",3"R",4"S",5"R",6"R")-3,4,5-trimethoxy-
6-(sulfonatooxymethyl)oxan-2-yl] oxyoxane-
2-carboxylate
CAS_number = 149920-56-9
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 3083444
DrugBank =
chemical_formula =
C=38 | H=55 | Na=9 | O=49 | S=7
molecular_weight = 1727.17683 g/mol
smiles = CO [C@@H] 1 [C@H] (O [C@@H] ( [C@@H] ( [C@H] 1OC)OC)O [C@H] 2 [C@@H] ( [C@H] ( [C@@H] (O [C@@H] 2C(=O) [O-] )O [C@@H] 3 [C@H] (O [C@@H] ( [C@@H] ( [C@H] 3OS(=O)(=O) [O-] )OS(=O)(=O) [O-] )O [C@H] 4 [C@@H] ( [C@H] ( [C@@H] (O [C@H] 4C(=O) [O-] )O [C@@H] 5 [C@H] (O [C@@H] ( [C@@H] ( [C@H] 5OS(=O)(=O) [O-] )OS(=O)(=O) [O-] )OC)COS(=O)(=O) [O-] )OC)OC)COS(=O)(=O) [O-] )OC)OC)COS(=O)(=O) [O-] . [Na+] . [Na+] . [Na+] . [Na+] . [Na+] . [Na+] . [Na+] . [Na+] . [Na+]
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 80-130 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Investigational
routes_of_administration = SubcutaneousIdraparinux sodium is an
anticoagulant medication with a similar chemical structure and the same method of action asfondaparinux , but with an elimination half-life about five to six times longer. It needs to be applied only once a week.as of|July 2007, it has completed the
Phase III clinical trial AMADEUS.Method of action
Idraparinux selectively blocks
coagulation factor Xa .See for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.
References
*cite journal|last=Turpie|first=AGG|coauthors=Gallus, AS, Hoek, JA|date=2001|title=A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement|journal=N. Engl. J. Med.|volume=344|issue=9|pages=619-625|url=http://content.nejm.org/cgi/content/short/344/9/619
*cite book|last=Steinhilber|coauthors=Schubert-Zsilavecz, Roth|title=Medizinische Chemie: Targets und Arzneistoffe|publisher=WVG Stuttgart|date=2004|language=German
Wikimedia Foundation. 2010.
